OPENING SHOT
Six Signals. One Direction.
The week running into June 4 delivered a dense cluster. Smith+Nephew launched the next-generation LEAF Patient Monitoring System. Tiger BioSciences published interim TIGERCAMP RCT data on caregraFT. Stramsen Biotech received written FDA feedback clearing the path to IND submission. Rice University published Nature Biomedical Engineering research on a cell-based cytokine factory patch. Plasmacure posted 62% wound closure rates in a new RCT alongside a new cold plasma R&D hire. Kent Imaging expanded SnapshotNIR into Hong Kong and Macau. And in the broader context framing all of it, the Washington Post ran an investigation today into the Trump administration's push to place AI directly in the clinical decision-making chain — not just in documentation, but in diagnosis and prescription.
The signals this week cluster around evidence maturation, international market access, and the emerging policy environment for AI in care delivery. Wound care companies ignoring the last of those three are going to be caught flat-footed. Here's the week.
See The Wound Market Like Never Before
317 companies scored and indexed across six dimensions. In-depth analysis across OPPS/PFS/LCD/WISeR. M&A heat maps and capital signals across wound care, limb salvage, and foot & ankle.
→ Access the 2026 BTK Innovation Index at belowtheknee.co/market-report
WOUND CARE
Commercial | Smith+Nephew Launches Next-Gen LEAF Patient Monitoring System
Smith+Nephew (LSE:SN, NYSE:SNN) announced the US commercial launch of the next-generation LEAF Patient Monitoring System on June 1, 2026. The platform is a cloud-hosted, data-driven pressure injury prevention solution using a wearable sensor to monitor patient mobility and deliver real-time turn status updates. The next-generation system features a redesigned interface developed in consultation with multidisciplinary nursing teams, improved EMR integration, and access via any hospital-approved device. Hospital-acquired pressure injuries contribute to approximately 60,000 annual deaths in the US, with a $26.8 billion annual economic burden. ECRI upgraded its Evidence Bar rating for LEAF to "favorable" earlier this year after reviewing the most recently published clinical outcomes data.
The BTK read: The LEAF launch is S+N executing a well-defined value-based care thesis: prevention platforms with quantifiable ROI will increasingly outperform pure treatment plays in institutional channels. The cloud-hosted architecture and EMR integration are the right infrastructure moves; adoption at scale depends on whether the data outputs are actionable enough to change nurse behavior at the bedside, not just report on it. The ECRI favorable rating provides independent clinical credibility that matters in institutional procurement conversations.
Regulatory | Stramsen Biotech Receives Positive FDA Pre-IND Feedback on SBX-1977
Stramsen Biotech (Houston, TX) announced on June 2, 2026 that it received written feedback from the FDA on its Pre-IND submission for SBX-1977, a botanical drug candidate targeting wound healing. FDA's written response, received April 21, 2026, indicated that the proposed chemistry, manufacturing and controls strategy and nonclinical package appear reasonable to support IND submission and a planned Phase 1 study. The agency also provided recommendations on clinical trial design, safety monitoring, pharmacokinetic assessments, and product quality controls. Stramsen expects to submit its IND in the coming weeks. Upon clearance, the company plans to initiate a Phase 1 study evaluating safety, tolerability, pharmacokinetics, and preliminary wound-healing activity in adults undergoing dermatologic surgical excision procedures. The company concurrently announced a Co-CFO structure, adding Kimberly Graper, CPA, JD, and John Griffin, MBA, MS, to strengthen capital markets capabilities.
The BTK read: This is a Pre-IND feedback note, not an approval — the regulatory milestone is that the FDA found the CMC and nonclinical strategy reasonable enough to proceed, which is meaningful but early. SBX-1977 is a botanical drug, a category with a specific and often slow FDA pathway. The flag here is that Stramsen is a small, pre-revenue company with a $19B self-reported valuation that has not been independently verified. The Co-CFO announcement and simultaneous search for investment banks signal they're in active fundraising mode. Worth watching for the IND submission and Phase 1 initiation as the next real milestone; until then, this is a pipeline story, not a commercial one.
Clinical Evidence | Tiger BioSciences Publishes Interim TIGERCAMP RCT Data for caregraFT
Tiger BioSciences announced publication of interim data from the ongoing TIGERCAMP randomized controlled trial (NCT06826339) on May 28, 2026. TIGERCAMP is a multicenter, prospective RCT evaluating caregraFT; a full-thickness placental membrane allograft as an adjunct to standard of care in patients with non-healing diabetic foot ulcers. Key interim findings: caregraFT plus SOC achieved complete wound closure in 46% of patients versus 28% for SOC alone; demonstrated a 61% mean percent area reduction versus 39% for SOC alone; showed a 96% Bayesian probability of wound closure benefit; and produced approximately 1.8x greater likelihood of closure. No product-related adverse events were observed at interim. The findings are planned for publication in the Journal of Chronic Wound Care Management and Research. The study's primary endpoint is complete wound closure at 12 weeks.
The BTK read: This is a CMS-1832-F story as much as a clinical one. Tiger is a CAMP company operating in the flat-rate environment — caregraFT needs to demonstrate clinical differentiation that justifies use and reimbursement in the new outpatient billing structure. The limitations are that this is interim data, the full trial is still running, and the 12-week primary endpoint read is still pending. This is competitive CAMP evidence in a category that needs it. Watch for the full publication and any LCD response.
Clinical Evidence | PlasmaCure Posts 62% Closure Rate in New RCT, Deepens R&D Team
PlasmaCure, developer of the PLASOMA cold atmospheric plasma device, reported new randomized clinical trial data showing PLASOMA plus standard care achieved wound closure in 62% of patients at 12 weeks, compared to 25% for standard care alone. CEO Bjorn Sprengers also presented at EWMA 2026 on building MedTech companies capable of surviving past the industry's valley of death. The company positioned these advances as evidence of clinical maturation and organizational readiness for broader commercial scaling.
The BTK read: A 62% vs 25% closure rate in a 12-week RCT is a headline-worthy clinical signal for cold plasma wound care. The mechanism is defensible — reactive oxygen and nitrogen species have measurable antimicrobial and tissue-stimulating effects, and the EWMA presentation gives this visibility in the European market where PlasmaCure is most advanced commercially. The open questions remain reimbursement pathway and US market entry — neither has been resolved. But PlasmaCure is building clinical credibility faster than most players in the emerging energy-based wound care space.
Policy & AI | The Trump Administration's AI Doctor Push — What It Means for Wound Care
The Washington Post published a major investigation yesterday (June 4, 2026) reporting that the Trump administration is actively laying groundwork to allow AI systems to perform diagnostic and prescriptive functions in American medicine — moving substantially beyond the AI scribe and documentation support tools already in clinical use. The administration's approach, connected to figures including Amy Gleason at DOGE and supported by broader deregulatory positioning at HHS, envisions AI agents operating in direct clinical decision-making roles, with physicians no longer required as intermediaries for certain categories of care.
The BTK read: This is the macro context for everything else in today's newsletter. The Adaptive Innovations $60M raise, the RENA clinical documentation agent from last week, the InkWell RTM platform — these are all pieces of the same infrastructure build. The policy question for wound care specifically is where AI clinical agents sit in the reimbursement and liability chain when they're involved in wound assessment, product selection, or care pathway decisions. CMS documentation error rates in surgical dressings are already running at 57.6% annually. If AI agents enter the prescriptive layer without clear liability frameworks, wound care companies face both an opportunity (better-documented orders, fewer improper payment clawbacks) and a risk (AI-driven formulary decisions that disadvantage complex biologics in favor of cost-optimized alternatives). This one is worth tracking closely.
INTERNATIONAL
Market Access | Kent Imaging Expands SnapshotNIR into Hong Kong and Macau via JCare Medical Technology
Kent Imaging announced a distribution agreement on June 2, 2026, establishing JCare Medical Technology Co. Limited as the sole distributor of SnapshotNIR in Hong Kong and Macau. SnapshotNIR is a portable, handheld near-infrared spectroscopy device providing non-invasive point-of-care measurement of tissue oxygen saturation, oxyhemoglobin, deoxyhemoglobin, and total hemoglobin. The device auto-calibrates across skin tones, is FDA-cleared and CE-marked, and acquires images in approximately 0.2 seconds. JCare, headquartered in Kowloon, is an established distributor of advanced wound care, compression therapy, and related medical technology across Hong Kong and Macau, with primary focus on large public hospital systems and private facilities. Kent Imaging's full Snapshot product suite now includes SnapshotNIR and SnapshotGLO, a bacterial autofluorescence imaging device that received FDA 510(k) clearance in 2025.
The BTK read: The Hong Kong and Macau partnership is a clean market-access move into a high-density, high-acuity healthcare market with a well-capitalized public hospital system. JCare's existing wound care and compression therapy portfolio gives SnapshotNIR an established sales channel rather than a cold start. The more interesting story is the full Snapshot suite — pairing near-infrared oxygenation imaging (SnapshotNIR) with bacterial autofluorescence imaging (SnapshotGLO) creates a tissue assessment platform that covers both the perfusion question and the bioburden question at the bedside. That combination has meaningful clinical value in DFU and limb salvage workflows. Watch for further APAC expansion as the commercial signal.
📅 UPCOMING EVENTS
June 7–10 | Nashville, TN 🔥 SAWC Spring 2026
June 12–14 | Chennai, India — 3rd Chennai Advanced Diabetic Foot & Wounds Conference — Hilton, Chennai
June 21 | St. Louis, MO — St. Louis Wound & Vascular Symposium — Hilton Frontenac
June 25–28 | Anaheim, CA — The Western Foot & Ankle Conference 2026 — Disneyland Hotel & Convention Center
August 6–9 | Nashville, TN 🔥 APMA Annual Scientific Meeting (The National) — Gaylord Opryland
September 10–11 | New Orleans, LA — IPAWS & Tissue Repair Summit (Kernexus) — The Ritz-Carlton
September 14–16 | Louisville, KY 🔥 NAWCO HEAL Conference 2026
September 23–27 | Kuala Lumpur, Malaysia 🔥 WUWHS 2026
October 15–18 | Las Vegas, NV 🔥 SAWC Fall 2026 — Caesars Palace
October 22–24 | Anaheim, CA 🔥 DFCon 2026 — JW Marriott
November 6 | Virtual — WoundCon Fall 2026
December 9–12 | Phoenix, AZ — Desert Foot Multi-Disciplinary Limb Salvage & Wound Care Conference
Below The Knee | belowtheknee.co Independent market intelligence for wound care, limb salvage, vascular intervention, and foot & ankle. Not subscribed? → newsletter.belowtheknee.co Forward this to one person in your network who works in this space.
See you next week. — Scott